This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanna, G Articles by Mathieu, A Search for Related Content PubMed PubMed Citation Articles by Sanna, G Articles by Mathieu, A Social Bookmarking                   What's this?

Central nervous system lupus: a clinical approach to therapy

Department of Rheumatology, Homerton University Hospital, London E9 6SR, UK, giovanni.sanna{at}homerton.nhs.uk

M L Bertolaccini

Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London SE1 7EH, UK

A Mathieu

Second Chair of Rheumatology, Department of Medical Sciences, University of Cagliari, 09100 Cagliari, Italy

Management of central nervous system (CNS) involvement still remains one of the most challenging problems in systemic lupus erythematosus (SLE). The best available evidence for the treatment of CNS lupus is largely based on retrospectiveseries, case reports and expert opinion. Current therapy is empirical and tailored to the individual patient. Symptomatic, immunosuppressiveand anticoagulant therapies are the main strategies for the management of CNS lupus. The choice depends on the most probable underlying pathogenic mechanism and the severity of the presenting neuropsychiatric symptoms. Thrombotic and nonthrombotic CNS disease needs to be differentiated and requires different management strategies. However, this is often challenging since many, if not most CNS manifestations, may be due to a combination of different pathogenic mechanisms and multiple CNS events may occur in the individual patient. Patients with mild manifestations may need symptomatic treatment only, whereas more severe acute nonthrombotic CNS manifestations may require pulse intravenouscyclophosphamide.Plasmapheresismay also be added in patients with more severe illness refractory to conventionaltreatment. Recently, the use of intrathecalmethotrexateand dexamethasone has been reported in a small series of patients, with a good outcome in patients with severe CNS manifestations.Anticoagulationis warranted in patients with thrombotic disease, particularlyin those with the antiphospholipid syndrome (APS). This article reviews the clinical approach to therapy in patients with CNS lupus.

Key Words: aPL • CNS • immunosuppression • ischemia • SLE

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. M. Everett, T. D. Graves, S. Lad, H. R. Jager, M. Thom, D. A. Isenberg, and M. G. Hanna Aggressive CNS lupus vasculitis in the absence of systemic disease activity Rheumatology, January 1, 2008; 47(1): 107 - 109. [Full Text] [PDF]

				H-H Yu, J-H Lee, L-C Wang, Y-H Yang, and B-L Chiang Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study Lupus, October 1, 2006; 15(10): 651 - 657. [Abstract] [PDF]

				F-G Lehnhardt, C Scheid, U Holtik, L Burghaus, M Neveling, P Impekoven, A Ruger, M Hallek, A H Jacobs, and A Rubbert Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction Lupus, April 1, 2006; 15(4): 240 - 243. [Abstract] [PDF]

				N. Sofat, O. Malik, and C.S. Higgens Neurological involvement in patients with rheumatic disease QJM, February 1, 2006; 99(2): 69 - 79. [Abstract] [Full Text] [PDF]

				G. SANNA, M. L. BERTOLACCINI, and G. R. V. HUGHES Hughes Syndrome, the Antiphospholipid Syndrome: A New Chapter in Neurology Ann. N.Y. Acad. Sci., June 1, 2005; 1051(1): 465 - 486. [Abstract] [Full Text] [PDF]

				L Barile-Fabris, R Ariza-Andraca, L Olguin-Ortega, L J Jara, A Fraga-Mouret, J M Miranda-Limon, J Fuentes de la Mata, P Clark, F Vargas, and J Alocer-Varela Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus Ann Rheum Dis, April 1, 2005; 64(4): 620 - 625. [Abstract] [Full Text] [PDF]

				S. Ferreira, D. P. D'Cruz, and G. R. V. Hughes Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology, April 1, 2005; 44(4): 434 - 442. [Abstract] [Full Text] [PDF]